Asterias Biotherapeutics Inc (NYSEAMERICAN:AST) was the target of a large growth in short interest in the month of January. As of January 31st, there was short interest totalling 430,397 shares, a growth of 19.2% from the January 15th total of 361,141 shares. Currently, 1.3% of the company’s stock are sold short. Based on an average trading volume of 288,497 shares, the days-to-cover ratio is presently 1.5 days.

Shares of NYSEAMERICAN:AST traded up $0.07 on Monday, reaching $0.90. The company had a trading volume of 101,500 shares, compared to its average volume of 172,043. Asterias Biotherapeutics has a 52-week low of $0.51 and a 52-week high of $2.30.

Asterias Biotherapeutics (NYSEAMERICAN:AST) last announced its quarterly earnings results on Friday, November 9th. The biotechnology company reported ($0.08) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.10) by $0.02. The company had revenue of $0.12 million during the quarter, compared to analysts’ expectations of $0.11 million.

Institutional investors have recently bought and sold shares of the company. Renaissance Technologies LLC acquired a new stake in shares of Asterias Biotherapeutics in the 2nd quarter worth $142,000. Creative Planning boosted its position in shares of Asterias Biotherapeutics by 11.0% in the 4th quarter. Creative Planning now owns 200,189 shares of the biotechnology company’s stock worth $124,000 after purchasing an additional 19,900 shares in the last quarter. Finally, Millennium Management LLC acquired a new stake in shares of Asterias Biotherapeutics in the 2nd quarter worth $663,000.

Separately, Zacks Investment Research upgraded Asterias Biotherapeutics from a “hold” rating to a “buy” rating and set a $1.25 price target on the stock in a report on Thursday, November 15th.

ILLEGAL ACTIVITY WARNING: “Asterias Biotherapeutics Inc (AST) Short Interest Up 19.2% in January” was originally reported by TheOlympiaReport and is the property of of TheOlympiaReport. If you are accessing this piece on another publication, it was illegally copied and republished in violation of U.S. & international trademark and copyright laws. The original version of this piece can be viewed at

Asterias Biotherapeutics Company Profile

Asterias Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing cell-based therapeutics to treat neurological conditions associated with demyelination, and cellular immunotherapies to treat cancer. Its clinical stage programs include AST-OPC1, an oligodendrocyte progenitor cell population derived from pluripotent stem cells that is in Phase I/IIa clinical trial for spinal cord injuries; AST-VAC2 is a non-patient-specific cancer immunotherapy derived from pluripotent stem cells for the treatment of non-small cell lung cancer; and AST-VAC1, a patient-specific cancer immunotherapy that has completed Phase II clinical trial for the treatment of acute myeloid leukemia.

Featured Story: Price to Earnings Ratio (PE)

Receive News & Ratings for Asterias Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Asterias Biotherapeutics and related companies with's FREE daily email newsletter.